Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials. The irreversible/pan-HER inhibitor neratinib (N) has proven more potent than L. However, the efficacy o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:NPJ Breast Cancer
Autori principali: Veeraraghavan, Jamunarani, Gutierrez, Carolina, Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Giuliano, Mario, Shea, Martin J., Mitchell, Tamika, Wang, Tao, Nanda, Sarmistha, Pereira, Resel, Davis, Robert, Goutsouliak, Kristina, Qin, Lanfang, De Angelis, Carmine, Diala, Irmina, Lalani, Alshad S., Nagi, Chandandeep, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8159999/
https://ncbi.nlm.nih.gov/pubmed/34045483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00274-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi